CERO THERAPEUTICS WTS 29

CERo Therapeutics has been denied continued listing on Nasdaq due to non-compliance with stockholders' equity requirements. The company plans to appeal the decision, seek OTC Markets trading, and continue clinical operations while exploring financing alternatives.

CERo Therapeutics Holdings, Inc. (CERO) has appointed Chris Ehrlich as its new CEO. The company is advancing the development of next-generation engineered T cell therapeutics for cancer treatment, with plans to initiate clinical trials for its lead product candidate CER-1236 in early 2025 for acute myeloid leukemia (AML).